Re: ImmuneRegen Strategic Collaboration

7 September 2010

                             Scancell Holdings Plc                             

                    (`Scancell Holdings' or the `Company')                     

                  Collaboration With ImmuneRegen BioSciences®                  
               Yields Positive Results in Cancer Vaccine Studies               

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer
vaccines, announces that a treatment utilising a DNA vaccine based on its
ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s
lead compound, Homspera®, has significantly improved the immune response of the
vaccine in an animal model. Follow-up studies are currently being performed to
optimize the effects of Homspera in enhancing the next generation of Scancell's
cancer vaccines.

Scancell recently announced the commencement of a Phase I clinical trial
utilizing its SCIB1 product being developed for the treatment of melanoma.
SCIB1 is a novel DNA vaccine being developed using Scancell's patented
ImmunoBody® technology. ImmunoBody® vaccines generate the high-avidity T-cells
that kill cancer cells, which may overcome the current limitations of most
cancer vaccines. A unique advantage of Scancell's Immunobody® technology is
that it specifically targets dendritic cells, leading to a significant
enhancement of the immune response.

ImmuneRegen's Homspera has previously been found to improve the efficacy of a
melanoma cancer vaccine in mice, resulting in persistent and specific immune
responses associated with inhibition of melanoma tumor growth. Additionally,
previous studies have demonstrated efficacy of Homspera in enhancing immune
responses to infectious disease vaccines, such as influenza. Both applications
are being aggressively developed by ImmuneRegen in combination with significant
academic and industry partners.

Professor Lindy Durrant, Chief Executive Officer of Scancell, commented:

"I am pleased with the results achieved by this collaboration to date and look
forward to continuing to work with ImmuneRegen as we progress with follow-up
studies."

Hal Siegel Ph.D., Chief Scientific Officer of ImmuneRegen, commented:

"We are pleased to see if we can positively augment immune responses elicited
by Scancell's ImmunoBody® vaccines. Based on our previous demonstration of
enhanced dendritic cell responses to TRP2-encoding DNA vaccine following
Homspera exposure, Scancell's ImmunoBody® vaccine technology presents a very
desirable developmental opportunity. We are very happy with our ongoing
relationship and recognize that ongoing studies could potentially benefit both
companies."

ImmuneRegen BioSciences, Inc.® is a wholly owned subsidiary of IR BioSciences
Holdings, Inc. (OTC BB:IRBS.OB)

For further information contact:

Scancell Holdings Plc                           + 44 (0)207 245 1100
                                                                   
Professor Lindy Durrant                                            
                                                                   
Hansard Communications                          + 44 (0)207 245 1100
                                                                   
John Bick/Kirsty Corcoran                                          
                                                                   
Zeus Capital - Nominated Adviser/Joint Broker   + 44 (0)161 831 1512
                                                             
                                                                   
Ross Andrews/Tom Rowley                                            
                                                                   
Matrix Corporate Capital LLP - Joint Broker     [phone]
                                                                   
Robert Naylor/Stephen Waterman                                     

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and has recently entered clinical trials.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.